Tag:
Dyloject
Latest Headlines
Latest Headlines
Myriad grabs pain drug in $91M Javelin buyout
Myriad Pharmaceuticals has snared Javelin Pharmaceuticals and its promising post-operative pain drug Dyloject in an all-stock deal initially valued at $91 million. Javelin (JAV) shareholders will
